At the 2026 MCDC Annual Meeting, Medigen scientists highlighted advanced progress on Lassa and VEEV virus vaccines, addressing a critical need for approved treatments against these emerging pathogens. There are no vaccines for Lassa and VEEV viruses. With GMP manufacturing and favorable toxicology results demonstrating the vaccines’ safety and immunogenicity, Medigen is currently advancing these vaccines to Phase 1 clinical trials.